PRQR

ProQR Therapeutics N.V.

2.00 USD

Last updated Dec 10, 20:21 UTC

Yesterday HIGH

$2.13

Yesterday LOW

$1.91

52w HIGH

$3.85

52w LOW

$1.11

EPS

-0.08

PE

-25.00

Next Earnings

Mar 27, 2024

Overview News Government Trades

ProQR Therapeutics N.V. stock is up 47.06% since 30 days ago. The next earnings date is Mar 27, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 70% of the previous 9 December’s closed higher than November.

ProQR Therapeutics N.V. engages in the discovery and development of RNA-based therapeutics. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber's congenital amaurosis 10 disease. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

Leiden, Netherlands

Website

proqr.com

Charles Gross

Wed Mar 29, 2023

ProQR Therapeutics Sent Request To SEC For Withdrawal Of Registration Statement On Form F-3

Pursuant to Rule 477 promulgated under the Securities Act of 1933, as amended (the "Securities Act"), ProQR Therapeutics N.V. (the "Company") hereby requests that the Securities and Exchange Commission (the "Commission") consent to the withdrawal of the Company's registration statement on Form F-3 (File No.
Lisa Levin

Wed Mar 29, 2023

S&P 500 Up 1%; Bluebird Bio Shares Plummet

U.S. stocks traded higher toward the end of trading, with the S&P 500 gaining over 1% on Wednesday. The Dow traded up 0.74% to 32,632.35 while the NASDAQ rose 1.51% to 11,893.07. The S&P 500, also rose, gaining, 1.14% to 4,016.45.
Lisa Levin

Wed Mar 29, 2023

Why Kodiak Sciences Shares Are Trading Higher By 18%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Gainers LogicMark, Inc. (NASDAQ: LGMK) shares jumped 76.1% to $0.2466 after the company announced financial results for the year ended 2022. The company reported FY22 revenue of $11.9 million.
Lisa Levin

Wed Mar 29, 2023

Nasdaq Rises 1%; US Pending Home Sales Increase In February

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 100 points on Wednesday. The Dow traded up 0.58% to 32,580.89 while the NASDAQ rose 1.09% to 11,843.85. The S&P 500, also rose, gaining, 0.90% to 4,006.83.
Lisa Levin

Wed Mar 29, 2023

US Stocks Open Higher, Dow Jumps Over 200 Points

U.S. stocks traded higher this morning, with the Dow Jones gaining over 200 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.72% to 32,628.42 while the NASDAQ rose 1.33% to 11,872.30. The S&P 500, also rose, gaining, 1.03% to 4,012.27.
Benzinga Insights

Wed Mar 29, 2023

Earnings Scheduled For March 29, 2023

Companies Reporting Before The Bell • NeoGenomics (NASDAQ:NEO) is estimated to report quarterly earnings at $0.16 per share on revenue of $195.54 million.
Benzinga Newsdesk

Wed Mar 29, 2023

ProQR Held Cash & Cash Equivalents Of €94.8M, With Cash Runway Expected To Fund Operations Into Mid-2026

This guidance excludes any additional potential future income from partnerships, including the potential Lilly opt-in fee of $50 M for 5 additional targets, milestone payments related to the Lilly
Benzinga Newsdesk

Wed Mar 29, 2023

ProQR Therapeutics FY EPS €(0.91) Up From €(0.96) YoY

ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of €(0.91) per share. This is a 5.21 percent increase over losses of €(0.96) per share from the same period last year.
Benzinga Insights

Tue Mar 28, 2023

Earnings Outlook For ProQR Therapeutics
Lisa Levin

Fri Dec 23, 2022

Tesla To $175? Here Are 10 Other Price Target Changes For Friday

Oppenheimer cut CarMax, Inc. (NYSE: KMX) price target from $100 to $75. . Oppenheimer analyst Brian Nagel maintained an Outperform rating on the stock. CarMax shares fell 1.3% to $56.47 in pre-market trading.